- Home
- EMD vs CELC Comparison
EMD vs CELC Comparison
Compare EMD & CELC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- EMD
- CELC
- Stock Information
- Founded
- EMD 2003
- CELC 2011
- Country
- EMD United States
- CELC United States
- Employees
- EMD N/A
- CELC N/A
- Industry
- EMD Finance/Investors Services
- CELC Medical Specialities
- Sector
- EMD Finance
- CELC Health Care
- Exchange
- EMD Nasdaq
- CELC Nasdaq
- Market Cap
- EMD 527.7M
- CELC 440.0M
- IPO Year
- EMD N/A
- CELC 2017
- Fundamental
- Price
- EMD $9.90
- CELC $11.60
- Analyst Decision
- EMD
- CELC Strong Buy
- Analyst Count
- EMD 0
- CELC 5
- Target Price
- EMD N/A
- CELC $30.80
- AVG Volume (30 Days)
- EMD 248.5K
- CELC 140.7K
- Earning Date
- EMD 01-01-0001
- CELC 08-13-2025
- Dividend Yield
- EMD 10.25%
- CELC N/A
- EPS Growth
- EMD N/A
- CELC N/A
- EPS
- EMD N/A
- CELC N/A
- Revenue
- EMD N/A
- CELC N/A
- Revenue This Year
- EMD N/A
- CELC N/A
- Revenue Next Year
- EMD N/A
- CELC N/A
- P/E Ratio
- EMD N/A
- CELC N/A
- Revenue Growth
- EMD N/A
- CELC N/A
- 52 Week Low
- EMD $7.85
- CELC $7.58
- 52 Week High
- EMD $9.55
- CELC $19.77
- Technical
- Relative Strength Index (RSI)
- EMD 66.75
- CELC 49.88
- Support Level
- EMD $9.75
- CELC $11.85
- Resistance Level
- EMD $9.85
- CELC $13.40
- Average True Range (ATR)
- EMD 0.08
- CELC 0.70
- MACD
- EMD 0.00
- CELC -0.09
- Stochastic Oscillator
- EMD 91.18
- CELC 35.83
About EMD Western Asset Emerging Markets Debt Fund Inc
Western Asset Emg Markets Debt Fund Inc is a non-diversified closed-end management investment company. Its primary investment objective is to seek high current income and the secondary objective is to seek capital appreciation.
About CELC Celcuity Inc.
Celcuity Inc is a clinical-stage biotechnology company pursuing development for oncology. The Company's lead therapeutic candidate is gedatolisib, a potent pan-PI3K and mTOR inhibitor. Its mechanism of action and pharmacokinetic properties are differentiated from other currently approved and investigational therapies that target PI3K or mTOR alone or together. A Phase 3 clinical trial, VIKTORIA-1, evaluating gedatolisib in combination with fulvestrant with or without palbociclib in patients with HR+/HER2- advanced breast cancer is currently enrolling patients.